Strategic Collaborations MRM Health has built a strong ecosystem through partnerships with VIB, DuPont, Oncode Institute, and Netherlands Cancer Institute, supported by a mix of regional and international investors. These relationships open channels for co-development, licensing, and access to expertise, laboratories, and trial networks—prime for business development discussions with pharma and biotech partners.

Clinical Momentum The MH002 program in ulcerative colitis is advancing into Phase IIb with FDA IND clearance, signaling near-term clinical milestones and potential collaboration opportunities around co-development or licensing. Partners can leverage shared clinical risk and access to the program's regulatory and trial execution expertise to accelerate value creation.

Funding Momentum MRM Health has secured non-dilutive VLAIO funding and a significant Series B/strategic investments, creating a strong funding runway for expansion of the microbiome platform and clinical programs. This funding profile provides opportunities for co-investment, milestone-based partnerships, and favorable deal structures for potential customers and collaborators.

Platform Advantage The proprietary microbiome platform enables rational selection and combination of live microbial strains into synergistic consortia, offering a flexible collaboration model for pharma seeking microbiome-based therapeutics. Opportunities include platform licensing, joint development, or outsourcing of preclinical/clinical optimization to accelerate programs.

Local Advantage Based in Ghent's biotech cluster with access to VIB and other academic networks, MRM Health can leverage regional trial sites, regulatory support, and research collaborations to accelerate deals with European CROs, academic partners, and regional investors.